A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-Daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) - Related Studies

A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-Daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)

This study is ongoing, but not recruiting participants.

Study NCT00622713. Last updated on August 5, 2008. Information provided by Novartis

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Alzheimer's Disease

2	Additional conditions recognized in this trial
		Alzheimer Disease

3	More general conditions related to this trial
		Brain Diseases
		Central Nervous System Diseases
		Delirium, Dementia, Amnestic, Cognitive Disorders
		Dementia
		Mental Disorders
		Nervous System Diseases
		Neurodegenerative Diseases
		Tauopathies

4	Interventions listed in this trial
		Rivastigmine transdermal patch

5	Additional drug interventions recognized in this trial
		Rivastigmine

6	More general drug interventions related to this trial
		Central Nervous System Agents
		Cholinergic Agents
		Cholinesterase Inhibitors
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Neuroprotective Agents
		Neurotransmitter Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protective Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Novartis